natgillin/translations-raw huggingface dataset:
Revasc consists of a vial containing a white powder and an ampoule containing clear, colourless solvent for solution for injection.
Revasc sestavljata viala, ki vsebuje bel prašek, in ampula, ki vsebuje bister, brezbarven vehikel za raztopino za injiciranje.
Revasc has no or negligible influence on the ability to drive and use machines.
Revasc nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Revatio (oral) is indicated for treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity.
Peroralna oblika zdravila Revatio je namenjena za zdravljenje odraslih bolnikov s pljučno arterijsko hipertenzijo v II. in III. funkcijskem razredu po razvrstitvi Svetovne zdravstvene organizacije (SZO) za izboljšanje sposobnosti za telesno obremenitev.
Revatio can cause dizziness and can affect vision.
Zdravilo Revatio lahko povzroči omotico in vpliva na vid.
Revatio contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Zdravilo Revatio vsebuje zdravilno učinkovino sildenafil, ki sodi med zdravila, ki jih imenujemo zaviralci fosfodiesteraze tipa 5 (PDE5).
Revatio does not require any special storage conditions.
Za shranjevanje zdravila niso potrebna posebna navodila.
Revatio has moderate influence on the ability to drive and use machines.
Zdravilo Revatio ima zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
Revatio is contraindicated in patients with severe hepatic impairment (Child-Pugh class C) (see section 4.3).
Revatio je kontraindiciran pri bolnikih s hudo okvaro jeter (razred C po Child-Pughu) (glejte poglavje 4.3).
Revatio is supplied as a white to off-white powder for oral suspension providing a white, grape flavoured oral suspension when constituted with water.
Zdravilo Revatio je bel do skoraj bel prašek za peroralno suspenzijo, iz katerega po rekonstituciji z vodo dobimo belo peroralno suspenzijo z okusom grozdja.
Revatio should not be administered to breast-feeding mothers.
Zdravila Revatio ne smete uporabljati pri doječih materah.
Revatio should not be given to children and adolescents under the age of 18.
Otroci in mladostniki, mlajši od 18 let, ne smejo jemati zdravila Revatio.
Revatio should not be given to children below 1 year of age.
Otroci, mlajši od 1 leta, ne smejo jemati zdravila Revatio.
Revatio should not be given to women who are breast-feeding since it is not known if the medicine passes into the breast milk.
Doječe matere ne smejo dobivati tega zdravila, ker ni znano, ali prehaja v materino mleko.
Revatio with food and drink
Zdravilo Revatio skupaj s hrano in pijačo
REVEL
Študija REVEL
Reversal effects were evident immediately after administration.
Učinek izničenja je bil zaznaven takoj po uporabi.
Reversal of both the microscopic and functional effects was complete within
Tako mikroskopski kot tudi funkcionalni učinki so popolnoma izginili
Reversal of effects of TMA has been observed after treatment was discontinued.
Po prenehanju zdravljenja so opažali izginotje učinkov TMA.
REVERSE
HRBTNA STRAN
reverse transcriptase inhibitor)
zaviralec reverzne transkriptaze)
Reversibility data are available among 35.3% of patients who developed neurotoxicity following docetaxel treatment at 100 mg/m² as single agent.
Podatki o reverzibilnosti so na voljo za 35,3 % bolnikov, pri katerih so se po zdravljenju z docetakselom
Reversibility data are available among 35.3% of patients who developed neurotoxicity following docetaxel treatment at 100 mg/m² as single agent.
Podatki o reverzibilnosti so na voljo za 35,3 % bolnikov, pri katerih so se po zdravljenju z docetakselomkot monoterapijo v odmerku 100 mg/m2 pojavili nevrotoksični učinki.
Reversibility of altered renal function has been observed with supportive treatment and discontinuation of potentially causative agents, including exenatide.
S podpornim zdravljenjem ter ukinitvijo potencialno vzročnih zdravil, vključno z eksenatidom, so opazili reverzibilnost spremenjenega delovanja ledvic.
Reversibility of the epithelial tympanic membrane blistering is also likely through epithelial migration, a natural self-cleaning and self–repair mechanism for the tympanic membrane and ear canal.
Reverzibilnost pojava mehurjev na epitelni membrani bobniča je verjetno prav tako posledica epitelne migracije, ki je naravni mehanizem samoočiščenja in samoobnavljanja bobniča in sluhovoda.
Reversible binding of ibrutinib to human plasma protein in vitro was 97.3% with no concentration dependence in the range of 50 to 1,000 ng/mL.
In vitro je reverzibilna vezava ibrutiniba na človeške plazemske beljakovine znašala 97,3% in v območju od 50 do 1.000 ng/ml ni bila odvisna od koncentracije.
Reversible clinical manifestations suggestive of neurotoxicity (e.g., nausea, vomiting, somnolence) have been reportedly associated with phenylacetate levels ranging from 499-1285 mcg/ml in cancer patients who received PAA intravenously.
O reverzibilnih kliničnih manifestacijah, ki so značilne za nevrotoksičnost (npr. slabost, bruhanje, somnolenca), so poročali v povezavi z ravnmi fenilbutirata v razponu od 499–1285 μg/ml pri bolnikih z rakom, ki so prejemali PAA intravensko.
Reversible haemolytic reactions have been observed in patients, especially those withnon-0 blood groups in immunomodulatory treatment.
Pri bolnikih, zlasti s krvnimi skupinami, ki niso 0, so pri imunomodulacijskem zdravljenju opazili reverzibilne hemolitične reakcije.
Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors or angiotensin II receptor antagonists.
Med sočasno uporabo litija in zaviralcev ACE ali zaviralcev receptorjev angiotenzina II so poročali o reverzibilnem zvišanju koncentracije litija v serumu in povečanju njegovega toksičnega delovanja.
Reversible inflammation at the injection site was noted in all groups (including controls) and was more severe in the 6 and 20 mg/kg dose groups.
Na mestih vboda je bilo pri vseh skupinah, vključno s kontrolnimi, opaziti vnetje (močneje pri skupinah z odmerkoma 6 mg/kg in 20 mg/kg), ki pa je bilo reverzibilno.
Reversible male infertility.
povratna neplodnost pri moških,
Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [area under the curve] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Pri nekaj psih, ki so prejemali 8 ali 10 mg/kg/dan (celotno izpostavljanje olanzapinu [površina pod krivuljo] je 12- do 15-krat večje kot pri človeku, ki dobi 12-miligramski odmerek), se je razvila reverzibilna nevtropenija, trombocitopenija ali anemija.
Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12 mg dose).
Pri nekaj psih, ki so prejemali 8 ali 10 mg/kg/dan (celotno izpostavljanje olanzapinu [AUC] je 12- do 15- krat večje kot pri človeku, ki dobi 12-miligramski odmerek), se je razvila reverzibilna nevtropenija, trombocitopenija ali anemija.
Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Pri nekaj psih, ki so prejemali 8 ali 10 mg/kg/dan (celotno izpostavljanje olanzapinu [AUC] je 12- do 15- krat večje kot pri človeku, ki dobi 12-miligramski odmerek), se je razvila reverzibilna nevtropenija, trombocitopenija ali anemija.
Reversible posterior leukoencephalopathy syndrome
Sindrom posteriorne reverzibilne levkoencefalopatije
Reversible posterior leukoencephalopathy syndrome
Sindrom reverzibilne posteriorne levkoencefalopatije
Reversible posterior leukoencephalopathy syndrome (a condition characterised by headache, confusion, seizures and visual loss)
indrom reverzibilne posteriorne levkoencefalopatije (bolezensko stanje, za katerega so značilni glavobol, zmedenost, epileptični napadi in okvara vida),
Reversible Posterior Leukoencephalopathy Syndrome (RPLS)
Sindrom reverzibilne posteriorne levkoencefalo-patije (RPLS)
Reversible posterior leukoencephalopathy syndrome (RPLS) may occur rarely during treatment with any asparaginase (see section 4.8).
Sindrom reverzibilne posteriorne levkoencefalopatije (RPLS) se lahko redko pojavi med zdravljenjem s katero koli asparaginazo (glejte poglavje 4.8).
Reversible posterior leukoencephalopathy syndrome (RPLS) may occur rarely during treatment with any asparaginase.
Sindrom reverzibilne posteriorne levkoencefalopatije (RPLS) se lahko redko pojavi med zdravljenjem s katero koli asparaginazo.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS), also known as Posterior Reversible Encephalopathy Syndrome (PRES) has been observed with cabozantinib.
Pri uporabi kabozantiniba so opazili sindrom reverzibilne posteriorne levkoencefalopatije (RPLS, Reversible Posterior Leukoencephalopathy Syndrome), znan tudi kot sindrom posteriorne reverzibilne encefalopatije (PRES, Posterior Reversible Encephalopathy Syndrome).
Reversible Posterior Leukoencephalopathy Syndrome (RPLS), also known as Posterior Reversible Encephalopathy Syndrome (PRES), has been observed with cabozantinib.
Z uporabo kabozantiniba so opazili sindrom reverzibilne posteriorne levkoencefalopatije (RPLS, Reversible Posterior Leukoencephalopathy Syndrome), znan tudi kot sindrom posteriorne reverzibilne encefalopatije (PRES, Posterior Reversible Encephalopathy Syndrome).
Reversible red colouration of the skin and mucous membranes (see above).
Reverzibilno rdeče obarvanje kože in sluznic (glejte zgoraj).
Reversible swelling of the brain (posterior reversible encephalopathy syndrome).
Otekanje možganov, ki lahko izzveni (sindrom posteriorne reverzibilne encefalopatije).
Reversible, minimal injection site reactions were noted in both dose groups.
Pri obeh skupinah je bilo opaziti minimalno reakcijo na mestih vboda, ki pa je bila reverzibilna.
Reversible, selective MAO-A inhibitor (moclobemide)
Selektivni reverzibilni zaviralec MAO-A (moklobemid)
Revestive 5 mg powder and solvent for solution for injection
Revestive 5 mg prašek in vehikel za raztopino za injiciranje teduglutid
Revestive has minor influence on the ability to drive and use machines.
Zdravilo Revestive ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
Revestive is a medicine that contains the active substance teduglutide.
Revestive je zdravilo, ki vsebuje zdravilno učinkovino teduglutid.
Revestive is a powder and solvent for solution for injection (5 mg powder in vial, 0.5 ml solvent in pre-filled syringe).
Zdravilo Revestive je prašek in vehikel za raztopino za injiciranje (5 mg praška v viali, 0,5 ml vehikla v napolnjeni injekcijski brizgi).
Revestive is for injection under the skin (subcutaneous injection).
Zdravilo Revestive je namenjeno injiciranju pod kožo (subkutana injekcija).
Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome.
Zdravilo Revestive je indicirano za zdravljenje bolnikov, starih 1 leto ali več, s sindromom kratkega črevesa.
Revestive is injected under the skin (subcutaneously) once daily.
Zdravilo Revestive se injicira pod kožo (subkutano) enkrat na dan.
Revestive is used after ‘intestinal adaptation’ has occurred (changes in the function of the bowel to compensate for its reduced size following surgery).
Zdravilo Revestive se uporablja po končani „prilagoditvi črevesa“ (spremembe v delovanju črevesa za prilagoditev na zmanjšano velikost po operaciji).
Revestive is used to treat adults and children from the age of 1 year with short bowel syndrome.
Zdravilo Revestive se uporablja za zdravljenje odraslih in otrok od enega leta dalje s sindromom kratkega črevesa.
Revestive must not be used in patients who have, or are suspected to have, a cancer.
Ne smejo ga uporabljati bolniki, ki imajo raka oziroma pri katerih obstaja sum, da imajo raka.
Revestive treatment induced expansion of the absorptive epithelium by significantly increasing villus height in the small intestine.
Zdravljenje z zdravilom Revestive je povzročilo povečanje absorpcijskega epitelija s pomembnim zvečanjem višine resic v tankem črevesu.
Revestive was shown to stimulate the growth of cells in the lining of the gut in experimental models.
Zdravilo Revestive se je pri poskusnih modelih izkazalo za učinkovito pri stimulaciji rasti celic v sluznici črevesa.
Revestive was studied in a 12-week, open-label, clinical study in 42 paediatric subjects aged 1 year through 14 years with SBS who were dependent on parenteral nutrition.
Zdravilo Revestive so proučevali v 12-tedenski odprti klinični študiji pri 42 pediatričnih preiskovancih s SKČ, starih od 1 do 14 let, ki so bili odvisni od parenteralne prehrane.
Revestive was studied in two main studies.
Zdravilo Revestive so proučevali v dveh glavnih študijah.
Review of post-marketing data suggests that patients aged 65 years or older report a higher frequency than the general population of the following events: Stevens-Johnson syndrome (SJS) and Drug Induced Hypersensitivity syndrome (DIHS).
Pregled podatkov iz obdobja trženja kaže, da je pri bolnikih, starih več kot 65 let, večja pogostnost naslednjih neželenih učinkov kot pri splošni populaciji: Stevens-Johnsonov sindrom (SJS) in z zdravili povzročen sindrom preobčutljivosti (DIHS – ''Drug Induced Hypersensitivity syndrome'').
Review of post-marketing data suggests that patients aged 65 years or older report a higher frequency than the general population of the following events: Stevens-Johnson syndrome (SJS) and Drug Induced Hypersensitivity syndrome (DIHS).
Pregled podatkov iz obdobja trženja kaže, da sta pri bolnikih, starih 65 let ali več, naslednja neželena učinka pogostejša kot pri splošni populaciji: Stevens-Johnsonov sindrom (SJS) in z zdravili povzročen sindrom preobčutljivosti (DIHS – Drug Induced Hypersensitivity syndrome).
Review of the PET reading criteria, including method of image review, criteria for interpretation, and images demonstrating the binary read methodology
Pregled kriterijev za odčitavanje PET-posnetkov, vključno z metodo pregledovanja slik, kriteriji za interpretacijo in slikami, ki prikazujejo metodologijo binarnega odčitavanja
Review of the PET reading criteria, including method of image review, criteria for interpretation, and images demonstrating the binary read methodology.
Pregled kriterijev odčitavanja PET posnetkov, vključno z metodo pregledovanja, kriterije za interpretacijo in posnetke, ki pojasnjujejo binarno metodologijo odčitavanja.
Review the LEMTRADA Patient Guide and Package Leaflet with your patient.
Opozorilno kartico bolnika in vodnik za bolnike, ki jemljejo zdravilo LEMTRADA, preglejte skupaj z bolnikom.
Revinty Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed
Revinty Ellipta 184 mikrogramov/22 mikrogramov prašek za inhaliranje, odmerjeni.
Revinty Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate /vilanterol
Revinty Ellipta 184 mikrogramov/22 mikrogramov prašek za inhaliranje, odmerjeni flutikazonfuroat/vilanterol
Revinty Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate/vilanterol
Revinty Ellipta 184 mikrogramov/22 mikrogramov prašek za inhaliranje, odmerjeni flutikazonfuroat/vilanterol
Revinty Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed
Revinty Ellipta 92 mikrogramov/22 mikrogramov prašek za inhaliranje, odmerjeni
Revinty Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate/vilanterol
Revinty Ellipta 92 mikrogramov/22 mikrogramov prašek za inhaliranje, odmerjeni flutikazonfuroat/vilanterol
Revinty Ellipta 92/22 microgram (92 micrograms of fluticasone furoate and 22 micrograms of vilanterol) can be used for the
Zdravilo Revinty Ellipta 92/22 mikrogramov (92 mikrogramov flutikazon furoata in 22 mikrogramov vilanterola) se lahko uporablja za zdravljenje astme in tudi kronične obstruktivne pljučne bolezni, medtem ko se lahko
Revinty Ellipta 92/22 microgram improved average FEV1 by 36 ml more than fluticasone furoate and by 172 ml more than placebo after 12 weeks of treatment; when it was used at a higher dose of 184/22 microgram it improved FEV1 by 193 ml more than fluticasone furoate and by 210 ml more than the comparator medicine fluticasone propionate after 24 weeks of treatment.
Zdravilo Revinty Ellipta 92/22 mikrogramov je po 12 tednih zdravljenja izboljšalo povprečni FEV1 za 36 ml več kot flutikazon furoat in za 172 ml več kot placebo; pri uporabi višjega odmerka 184/22 mikrogramov je zdravilo po 24 tednih zdravljenja izboljšalo FEV1 za 193 ml več kot flutikazon furoat in za 210 ml več kot primerjalno zdravilo s flutikazon propionatom.
Revinty Ellipta at all strengths was more effective in reducing the number of COPD flare-ups than vilanterol alone.
Zdravilo Revinty Ellipta je bilo pri vseh jakostih učinkovitejše pri zmanjšanju števila poslabšanj simptomov kronične obstruktivne pljučne bolezni kot samostojni vilanterol.
Revinty Ellipta can only be obtained with a prescription.
Izdaja zdravila Revinty Ellipta je le na recept.
Revinty Ellipta contains two active substances.
Zdravilo Revinty Ellipta vsebuje dve zdravilni učinkovini.
Revinty Ellipta is a medicine that contains the active substances fluticasone furoate and vilanterol.
Revinty Ellipta je zdravilo, ki vsebuje zdravilni učinkovini flutikazon fuorat in vilanterol.
Revinty Ellipta is a white powder.
Revinty Ellipta je bel prašek.
Revinty Ellipta is also used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults who have had exacerbations (flare–ups) of the disease in the past despite regular treatment.
Zdravilo Revinty Ellipta se uporablja tudi za zdravljenje simptomov kronične obstruktivne pljučne bolezni (KOPB) pri odraslih s poslabšanjem simptomov bolezni v preteklosti kljub rednemu zdravljenju.
Revinty Ellipta should not be used in conjunction with other long-acting beta2-adrenergic agonists or medicinal products containing long- acting beta2-adrenergic agonists.
Zdravila Revinty Ellipta se ne sme uporabljati skupaj z drugimi dolgodelujočimi agonisti adrenergičnih receptorjev beta2 ali z zdravili, ki vsebujejo dolgodelujoče agoniste adrenergičnih receptorjev beta2.
Revinty Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing.
Zdravila Revinty Ellipta se ne sme uporabljati za olajšanje nenadnega napada zasoplosti ali piskajočega dihanja.
Revinty Ellipta should only be considered for pregnant women if the expected benefits outweigh the risks.
Zdravilo Revinty Ellipta se lahko med nosečnostjo uporablja le, če pričakovana korist prevladuje nad tveganjem.
RevitaCAM 5mg/ml oromucosal spray for Dogs
RevitaCAMcam 5 mg/ml oralno pršilo za pse
RevitaCAM contains meloxicam, which belongs to a class of medicines called non-steroidal anti- inflammatory drugs (NSAIDs).
Zdravilo RevitsCAM vsebuje meloksikam, ki spada v skupino zdravil, imenovanih nesteroidna protivnetna zdravila (NSPVZ).
RevitaCAM is presented in:
Zdravilo RevitaCAM je na voljo v:
Revlimid 10 mg hard capsules
Revlimid 10 mg trde kapsule
Revlimid 10 mg hard capsules are blue-green/pale yellow, with “REV 10 mg” written on them.
Zdravilo Revlimid 10 mg trde kapsule so modrozelene/bledorumene z napisom "REV 10 mg".
Revlimid 10 mg hard capsules lenalidomide
Revlimid 10 mg trde kapsule lenalidomid
Revlimid 10 mg hard capsules:
Revlimid 10 mg trde kapsule:
Revlimid 15 mg hard capsules
Revlimid 15 mg trde kapsule
Revlimid 15 mg hard capsules are pale blue/white, with “REV 15 mg” written on them.
Zdravilo Revlimid 15 mg trde kapsule so bledomodre/bele z napisom “REV 15 mg”.
Revlimid 15 mg hard capsules lenalidomide
Revlimid 15 mg trde kapsule lenalidomid
Revlimid 15 mg hard capsules:
Revlimid 15 mg trde kapsule:
Revlimid 2.5 mg hard capsules
Revlimid 2,5 mg trde kapsule
Revlimid 2.5 mg hard capsules are blue-green/white, with “REV 2.5 mg” written on them.
Zdravilo Revlimid 2,5 mg trde kapsule so modrozelene/bele z napisom "REV 2.5 mg".
Revlimid 2.5 mg hard capsules lenalidomide
Revlimid 2,5 mg trde kapsule lenalidomid
Revlimid 2.5 mg hard capsules Revlimid 5 mg hard capsules Revlimid 7.5 mg hard capsules Revlimid 10 mg hard capsules Revlimid 15 mg hard capsules Revlimid 20 mg hard capsules Revlimid 25 mg hard capsules
Revlimid 2,5 mg trde kapsule Revlimid 5 mg trde kapsule Revlimid 7,5 mg trde kapsule Revlimid 10 mg trde kapsule Revlimid 15 mg trde kapsule Revlimid 20 mg trde kapsule Revlimid 25 mg trde kapsule
Revlimid 2.5 mg hard capsules:
Revlimid 2,5 mg trde kapsule:
Revlimid 20 mg hard capsules
Revlimid 20 mg trde kapsule
Revlimid 20 mg hard capsules are blue-green/pale blue, with “REV 20 mg” written on them.
Zdravilo Revlimid 20 mg trde kapsule so modrozelene/bledomodre z napisom “REV 20 mg”.
Revlimid 20 mg hard capsules lenalidomide
Revlimid 20 mg trde kapsule lenalidomid
Revlimid 20 mg hard capsules:
Revlimid 20 mg trde kapsule:
Revlimid 25 mg hard capsules
Revlimid 25 mg trde kapsule
Revlimid 25 mg hard capsules arewhite, with “REV 25 mg” written on them.
Revlimid 25 mg trde kapsule so bele z napisom “REV 25 mg”.
Revlimid 25 mg hard capsules lenalidomide
Revlimid 25 mg trde kapsule lenalidomid
Revlimid 25 mg hard capsules:
Revlimid 25 mg trde kapsule:
Revlimid 5 mg hard capsules
Revlimid 5 mg trde kapsule
Revlimid 5 mg hard capsules are white, with “REV 5 mg” written on them.
Zdravilo Revlimid 5 mg trde kapsule so bele z napisom "REV 5 mg".
Revlimid 5 mg hard capsules lenalidomide
Revlimid 5 mg trde kapsule lenalidomid
Revlimid 5 mg hard capsules:
Revlimid 5 mg trde kapsule:
Revlimid 7.5 mg hard capsules
Revlimid 7,5 mg trde kapsule
Revlimid 7.5 mg hard capsules are pale yellow/white, with “REV 7.5 mg” written on them.
Zdravilo Revlimid 7,5 mg trde kapsule so bledorumene/bele z napisom “REV 7.5 mg”.
Revlimid 7.5 mg hard capsules lenalidomide
Revlimid 7,5 mg trde kapsule lenalidomid
Revlimid 7.5 mg hard capsules:
Revlimid 7,5 mg trde kapsule:
Revlimid and the medicines you take in combination with Revlimid are taken on certain days over 4 weeks (28 days).
Zdravilo Revlimid in zdravila, ki jih jemljete v kombinaciji z zdravilom Revlimid, se jemljejo na določene dneve znotraj 4 tednov (28 dni).
Revlimid can stop the signs and symptoms of multiple myeloma getting worse.
Zdravilo Revlimid lahko zaustavi slabšanje znakov in simptomov diseminiranega plazmocitoma.
Revlimid capsules contain lactose.
Kapsule Revlimid vsebujejo laktozo.
Revlimid capsules should be taken at about the same time on the scheduled days.
Kapsule zdravila Revlimid je treba jemati na načrtovane dni ob približno istem času.
Revlimid contains lactose
Zdravilo Revlimid vsebuje laktozo
Revlimid contains lactose.
Zdravilo Revlimid vsebuje laktozo.
Revlimid contains the active substance ‘lenalidomide’.
Zdravilo Revlimid vsebuje zdravilno učinkovino, ki se imenuje "lenalidomid".
Revlimid has been studied in two main studies involving 704 patients with previously treated multiple myeloma.
Zdravilo Revlimid so raziskali v dveh glavnih študijah, ki sta vključevali 704 bolnike s predhodno zdravljenim multiplim mielomom.
Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Zdravilo Revlimid v kombinaciji z deksametazonom je indicirano za zdravljenje diseminiranega plazmocitoma pri odraslih bolnikih, ki so predhodno prejemali vsaj eno zdravljenje.
Revlimid in patients with multiple myeloma who have had at least one other type of treatment before
Zdravilo Revlimid pri bolnikih z diseminiranim plazmocitomom, ki so se že prej zdravili z vsaj eno drugo vrsto zdravila
Revlimid is a cancer medicine that contains the active substance lenalidomide.
Revlimid je zdravilo za zdravljenje raka, ki vsebuje zdravilno učinkovino lenalidomid.
Revlimid is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant (see section 4.2).
Zdravilo Revlimid je indicirano za zdravljenje odraslih bolnikov s predhodno nezdravljenim diseminiranim plazmocitomom, ki niso primerni za presaditev (glejte poglavje 4.2).